Mechanisms of resistance to EGFR targeted therapies

Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment

(2012) Caroline Nunes-Xavier et al.   Anti-Cancer Agents in Medicinal Chemistry

EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma

(2012) Carolina Navas et al.   CANCER CELL

EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

(2012) Christine M. Ardito et al.   CANCER CELL

HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair

(2012) S. Nowsheen et al.   CANCER RESEARCH

Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance

(2012) Takenori Ogawa et al.   CELL CYCLE

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

(2012) Giorgio V. Scagliotti et al.   Clinical Lung Cancer

Treatment of nonsmall cell lung cancer

(2012) Corey A. Carter et al.   CURRENT OPINION IN ONCOLOGY

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

A Novel Classification of Lung Cancer into Molecular Subtypes

(2012) Lisandra West et al.   PLoS One

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted therapy in head and neck cancer

(2012) S. K. Kundu et al.   TUMOR BIOLOGY

Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers

(2012) Krister J. Barkovich et al.   Cancer Discovery

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

(2012) Dalia Ercan et al.   Cancer Discovery

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR

(2011) Paul Workman et al.   CANCER CELL

Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult Mouse Lung

(2011) Kate D. Sutherland et al.   CANCER CELL

Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)

(2011) C.P. Belani et al.   CANCER TREATMENT REVIEWS

Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

(2011) I. S. Donev et al.   CLINICAL CANCER RESEARCH

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations

(2011) R. Rosell et al.   CLINICAL CANCER RESEARCH

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

(2011) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Pancreatic ductal cells in development, regeneration, and neoplasia

(2011) Maximilian Reichert et al.   JOURNAL OF CLINICAL INVESTIGATION

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

(2011) Kenichi Suda et al.   Journal of Thoracic Oncology

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

(2011) Trever G. Bivona et al.   NATURE

Inflammation meets cancer, with NF-κB as the matchmaker

(2011) Yinon Ben-Neriah et al.   NATURE IMMUNOLOGY

EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer

(2011) Melissa Oliveira-Cunha et al.   PANCREAS

Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer

(2011) Somaira Nowsheen et al.   PLoS One

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors

(2011) A. C. Faber et al.   Cancer Discovery

In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs

(2011) Neelesh Sharma et al.   Therapeutic Advances in Medical Oncology

SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24- Phenotype

(2010) Poornima Bhat-Nakshatri et al.   BMC CANCER

The role of the miR-200 family in epithelial-mesenchymal transition

(2010) Perry S. Mongroo et al.   CANCER BIOLOGY & THERAPY

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report

(2010) N. Girard et al.   CLINICAL CANCER RESEARCH

Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung

(2010) Naheed Alam et al.   Clinical Lung Cancer

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

(2010) R. Porta et al.   EUROPEAN RESPIRATORY JOURNAL

Targeted Therapeutic Agents for Colorectal Cancer

(2010) Cheng E. Chee et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Germ-Line and Somatic Presentations of the EGFR T790M Mutation in Lung Cancer

(2010) Ludmila Prudkin et al.   Journal of Thoracic Oncology

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

(2010) D Ercan et al.   ONCOGENE

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

(2010) I. Vivanco et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment

(2009) Natalia Jura et al.   CELL

Ras Activity Levels Control the Development of Pancreatic Diseases

(2009) Baoan Ji et al.   GASTROENTEROLOGY

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

(2009) Monica Red Brewer et al.   MOLECULAR CELL

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)

(2009) Yixuan Gong et al.   PLoS One

Antibody-Based Therapy for Solid Tumors

(2008) Li Yan et al.   CANCER JOURNAL

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

(2008) J.-Y. Wu et al.   CLINICAL CANCER RESEARCH

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

(2008) J. Bean et al.   CLINICAL CANCER RESEARCH

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer

(2008) A. Tatematsu et al.   CLINICAL CANCER RESEARCH

Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations

(2008) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells

(2008) Yu-Chih Chen et al.   PLoS One

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA